SCHEMBL6786019

SCHEMBL6786019

CC(=O)c1ccc(CCC(=O)O)cc1

nearest known ligand 0.79

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.79
FFAR1 O14842 7/20 0.61
KMT2A Q03164 2/20 0.59
KEAP1 Q14145 1/20 0.59
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 2/20 0.55
MMP12 P39900 1/20 0.54
MMP13 P45452 1/20 0.54
FFAR4 Q5NUL3 2/20 0.53
SRD5A2 P31213 1/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
EPHX2 P34913 1/20 0.51
NR1H4 Q96RI1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL82223 0.88 HSD17B10 (1.00) HSD17B10FFAR1KMT2ALMNAL3MBTL1
SCHEMBL2212719 0.86 HSD17B10 (0.89) HSD17B10FFAR1KMT2ALMNAL3MBTL1
SCHEMBL4623244 0.85 HSD17B10 (0.63) HSD17B10KMT2ALMNAL3MBTL1MMP12
SCHEMBL25175631 0.85 HSD17B10 (0.86) HSD17B10KMT2ALMNAL3MBTL1MMP12
SCHEMBL19784149 0.85 HSD17B10 (0.86) HSD17B10KMT2ALMNAL3MBTL1MMP12
SCHEMBL9818052 0.84 KMT2A (0.73) HSD17B10KMT2ALMNAL3MBTL1MMP12
SCHEMBL69746 0.84 FFAR1 (0.81) FFAR1KEAP1LMNAL3MBTL1FFAR4
SCHEMBL10415943 0.84 FFAR1 (0.58) HSD17B10FFAR1KEAP1LMNAL3MBTL1
SCHEMBL6471357 0.84 HSD17B10 (0.62) HSD17B10FFAR1KMT2ALMNAL3MBTL1
SCHEMBL264975 0.83 FFAR1 (0.65) HSD17B10FFAR1KEAP1L3MBTL1FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085564-A1 LYSINE ACETYLTRANSFERASE INHIBITORS Kronos Bio, Inc. (US) 2025-04-24 WO disclosed
WO-2025085554-A1 LYSINE ACETYLTRANSFERASE INHIBITORS Kronos Bio, Inc. (US) 2025-04-24 WO disclosed
CN-115403459-A Preparation method of 1, 4-dicarbonyl compound 广州自远生物科技有限公司 2022-11-29 CN disclosed
US-6818780-B2 APPLICATION IN MEDICINE FOR TREATMENT OF DISORDERS OF IMMUNOLOGICAL SYSTEM CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2004-11-16 US disclosed
EP-1284263-B1 DERIVATIVES OF P- HYDROXY PHENYL PROPIONIC ACID AS ANTIPROLIFERATIVE AGENTS CONSEJO SUPERIOR INVESTIGACION (ES) 2003-12-10 EP disclosed
US-20030199575-A1 P-hydroxyphenyl propionic acid derivatives as antiproliferative agents CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2003-10-23 US disclosed
EP-1284263-A1 DERIVATIVES OF P- HYDROXY PHENYL PROPIONIC ACID AS ANTIPROLIFERATIVE AGENTS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2003-02-19 EP disclosed
WO-2002102301-A2 SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2002-12-27 WO disclosed
US-6380218-B1 FOR THERAPY OF RESPIRATORY, ALLERGIC, AND INFLAMMATORY DISORDERS COMPRISING ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ACUTE RESPIRATORY DISEASE SYNDROME, PULMONARY HYPERSENSITIVITY, AND ALLERGIC RHINITIS IN A MAMMAL PFIZER INC 2002-04-30 US disclosed
EP-0971894-A1 NICOTINAMIDE DERIVATIVES Pfizer Products Inc. (US) 2000-01-19 EP disclosed
WO-1998045268-A1 NICOTINAMIDE DERIVATIVES PFIZER PRODUCTS INC. (US) 1998-10-15 WO disclosed
US-4559221-A COMBINED WITH PHYSIOLOGICALLY ACTIVE COMPONENT AND LABELLED WITH TECHNETIUM; BLOOD CIRCULATION, CANCER DETECTION NIHON MEDI-PHYSICS CO., LTD. (JP) 1985-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199575-A1 P-hydroxyphenyl propionic acid derivatives as antiproliferative agents P4HA1, PAH, VHL HSD17B10 755/4885FFAR1 1492/4885KMT2A 4021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.